Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07474545Phase 1Not Yet Recruiting

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KL0011034 Injection in Healthy Volunteers

Role: lead

NCT07240675Phase 1Recruiting

Single-dose,First-in-human of KLA478

Role: lead

NCT07171034Phase 1Recruiting

A Phase I Study of KLA318-2 Nanocrystal Injection

Role: lead

NCT03050164Phase 1Completed

Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions

Role: lead

NCT03050177Phase 1Completed

Bioequivalence Study of Gefitinib Tablets Under Fed Conditions

Role: lead

All 5 trials loaded